术前血清促甲状腺素水平预测正常功能甲状腺结节性质的作用分析

曾泉; 刘杰; 朱江; 胡国华

doi:10.13201/j.issn.1001-1781.2014.24.007

术前血清促甲状腺素水平预测正常功能甲状腺结节性质的作用分析

- 重庆医科大学附属第一医院耳鼻咽喉科(重庆, 400016)
基金项目:
国家临床重点专科建设项目经费资助(卫办医政函[2012]649号)

详细信息

通讯作者: 胡国华,E-mail:hghcq@sina.com

中图分类号: R736.1

收稿日期: 2014-09-12

Association between preoperative serum thyroid-stimulating hormone level and nonfunctioning malignant nodule thyroid disease

- Department of Otolaryngology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

More Information

Corresponding author: HU Guohua, E-mail: hghcq@sina.com

Received Date: 12 September 2014

摘要

摘要: 目的:观察术前血清促甲状腺素(TSH)水平与正常功能甲状腺结节的临床病理特征,探讨TSH水平是否为区分正常功能甲状腺结节良恶性的指标,以及TSH水平与甲状腺癌发病的关系。方法:回顾性分析108例(甲状腺乳头状癌25例,良性83例)行甲状腺手术的正常功能甲状腺结节患者的术前血清TSH水平、性别、年龄、结节个数以及肿瘤病理类型,并探讨血清TSH水平与甲状腺结节良恶性的关系,Logistic多因素分析预测甲状腺癌的发病因素。结果:良性组术前血清TSH水平为(1.16±0.85)mIU/L,恶性组术前血清TSH水平为(1.94±1.01)mIU/L,两组间比较差异有统计学意义(P<0.05)。高于人群平均TSH水平(1.4~3.5 mIU/L)组较低于人群平均TSH水平(0.35~1.40 mIU/L)组发生甲状腺癌概率更高(35.9% vs 15.9%,P＜0.05)。多因素分析血清TSH水平高(OR=10.913,P=0.001)、男性(OR=4.845,P=0.028)及年龄≥45岁(OR=10.831,P=0.001)均为发生甲状腺癌的独立危险因素。结论:术前血清TSH水平检测有利于区别正常功能甲状腺结节良恶性,血清TSH水平高、男性、年龄≥45岁是甲状腺癌发病的预测指标。
- 甲状腺肿瘤 /
- 促甲状腺素 /
- 甲状腺结节
Abstract: Objective:To investigate whether serum thyroid-stimulating hormone(TSH) levels are of value in predicting malignancy in patients with nodular thyroid disease. The relationship between TSH levels and thyroid cancer incidence was also investigated.Method:One hundred and eight patients with thyroid tumors who underwent surgical treatment were included in this study (25 cases of papillary thyroid cancer and 83 cases of benign tumors). The data of their preoperative serum TSH level, gender, age, number of tumors detected by ultrasonic inspection, and pathological type were retrospectively analyzed, and their association with thyroid cancer incidence was explored. Logistic regression analysis was used to predict thyroid cancer risk factors. Result:Patients with malignancy had a higher mean value of TSH than that of the patients with benignancy[(1.94±1.01)mIU/L vs (1.16±0.85)mIU/L, respectively; P<0.05]. Compared with the patients below the population mean, patients above the population mean had a significantly higher malignancy rate (35.9% vs 15.9%,P<0.05). High serum TSH level (OR=10.913, P=0.001), male (OR=4.845, P=0.028) and age ≥ 45 (OR=10.831,P=0.001) are independent risk factors of thyroid cancer. Conclusion:The preoperative serum TSH level may be useful in predicting the probability of cancer. The high serum TSH level, male, age ≥ 45 are risk factors of thyroid cancer.
- thyroid neoplasms /
- thyroid stimulating hormone /
- thyroid nodule

HTML全文

参考文献(14)

[1]	FIORE E, VITTI P.Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease[J].J Clin Endocrinol Metab, 2012, 97:1134-1145.
[2]	CHAN A O, IU Y P, SHEK C C.The reference interval of thyroid-stimulating hormone in Hong Kong Chinese[J].J Clin Pathol, 2011, 64:433-436.
[3]	KRATZSCH J, FIEDLER G M, LEICHTLE A, et al.New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultraso-nography of the thyroid[J].Clin Chem, 2005, 51:1480-1486.
[4]	DAVIES L, WELCH H G.Increasing incidence of thyroid cancer in the United States, 1973-2002[J].J Am Med Assoc, 2006, 295:2164-2167.
[5]	ZHANG B, JIANG Y X, LIU J B, et al.Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules[J].Thyroid, 2010, 20:51-57.
[6]	ZAFON C, OBIOLS G, BAENA J A, et al.Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size[J].J Thyroid Res, 2012, 2012:530721.
[7]	JIN J, MACHEKANO R, MCHENRY C R.The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease[J].Am J Surg, 2010, 199:294-297.
[8]	FRANCO A T, MALAGUARNERA R, REFETOFF S, et al.Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice[J].Proc Natl Acad Sci U S A, 2011, 108:1615-1620.
[9]	BIONDI B, COOPER D S.Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer[J].Thyroid, 2010, 20:135-146.
[10]	MANN K.Evaluation of risk in autonomously functioning thyroid nodules[J].Exp Clin Endocrinol Diabetes, 1998, 106Suppl 4:S23-26.
[11]	MCHENRY C R, HUH E S, MACHEKANO R N.Is nodule size an independent predictor of thyroid malignancy[J]?Surgery, 2008, 144:1062-1068.
[12]	HAYMART M R.Understanding the relationship between age and thyroid cancer[J].Oncologist, 2009, 14:216-221.
[13]	史良凤, 关海霞, 李玉姝, 等.术前血清促甲状腺素水平与甲状腺结节良恶性关系的研究[J].中华内分泌代谢杂志, 2010, 26 (3):213-214.
[14]	李建周, 金勇君, 刘欣, 等.血清促甲状腺素水平与甲状腺癌发病的相关性[J].中华肿瘤杂志, 2011, 33 (12):921-924.